{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:05:41Z","timestamp":1793502341536,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ajpc.2024.100638","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T12:08:06Z","timestamp":1707134886000},"page":"100638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Emerging therapies for MASLD and their impact on plasma lipids"],"prefix":"10.1016","volume":"17","author":[{"given":"Madison","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amon","family":"Asgharpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7560-9521","authenticated-orcid":false,"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-5551","authenticated-orcid":false,"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2024.100638_bib0001","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.ajpc.2024.100638_bib0002","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpc.2024.100638_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/124958","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-analysis","volume":"2013","author":"Lu","year":"2013","journal-title":"Int J Endocrinol"},{"issue":"6","key":"10.1016\/j.ajpc.2024.100638_bib0004","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.ajpc.2024.100638_bib0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpc.2024.100638_bib0006","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.atherosclerosis.2022.07.010","article-title":"Impact of NAFLD and its pharmacotherapy on lipid profile and CVD","volume":"355","author":"Wang","year":"2022","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ajpc.2024.100638_bib0007","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.hfc.2012.06.013","article-title":"Epicardial steatosis, insulin resistance, and coronary artery disease","volume":"8","author":"Toth","year":"2012","journal-title":"Heart Fail Clin"},{"issue":"9972","key":"10.1016\/j.ajpc.2024.100638_bib0008","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ajpc.2024.100638_bib0009","article-title":"Therapy for nonalcoholic fatty liver disease: current options and future directions","volume":"43","author":"P","year":"2021","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.ajpc.2024.100638_bib0010","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpc.2024.100638_bib0011","unstructured":"Transplant Pathology Internet Services. Accessed October 9, 2023. https:\/\/tpis.upmc.com\/changebody.cfm?url=\/tpis\/schema\/NAFLD2006.jsp."},{"issue":"7","key":"10.1016\/j.ajpc.2024.100638_bib0012","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hep4.1079","article-title":"Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic","volume":"1","author":"Filozof","year":"2017","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.ajpc.2024.100638_bib0013","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ajpc.2024.100638_bib0014","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ajpc.2024.100638_bib0015","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2013.12.018","article-title":"Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations","volume":"60","author":"de L\u00e9dinghen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpc.2024.100638_bib0016","series-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis b infection","year":"2015"},{"issue":"5","key":"10.1016\/j.ajpc.2024.100638_bib0017","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3390\/diagnostics11050842","article-title":"Magnetic resonance spectroscopy of hepatic fat from fundamental to clinical applications","volume":"11","author":"Pasanta","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ajpc.2024.100638_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101167","article-title":"Imaging biomarkers of NAFLD, NASH, and fibrosis","volume":"50","author":"Ajmera","year":"2021","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.ajpc.2024.100638_bib0019","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.ajpc.2024.100638_bib0020","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2036.2008.03869.x","article-title":"Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis","volume":"29","author":"Loomba","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ajpc.2024.100638_bib0021","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2010.04467.x","article-title":"Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis","volume":"32","author":"Rakoski","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"10019","key":"10.1016\/j.ajpc.2024.100638_bib0022","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ajpc.2024.100638_bib0023","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ajpc.2024.100638_bib0024","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/metabo11020087","article-title":"The effects of SGLT2 inhibitors on lipid metabolism","volume":"11","author":"Szekeres","year":"2021","journal-title":"Metabolites"},{"issue":"9","key":"10.1016\/j.ajpc.2024.100638_bib0025","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.ajpc.2024.100638_bib0026","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"issue":"18","key":"10.1016\/j.ajpc.2024.100638_bib0027","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2024.100638_bib0028","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Vitamin e dosing study (VEDS): a dose finding study of vitamin e for the treatment of adult NAFLD. clinicaltrials.gov; 2023. Accessed December 31, 2022. https:\/\/clinicaltrials.gov\/study\/NCT04801849."},{"issue":"22","key":"10.1016\/j.ajpc.2024.100638_bib0029","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajpc.2024.100638_bib0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ajpc.2024.100638_bib0031","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1872-034X.2010.00644.x","article-title":"Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study","volume":"40","author":"Yoneda","year":"2010","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.ajpc.2024.100638_bib0032","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00535-010-0291-8","article-title":"Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease","volume":"46","author":"Park","year":"2011","journal-title":"J Gastroenterol"},{"issue":"4","key":"10.1016\/j.ajpc.2024.100638_bib0033","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ajpc.2024.100638_bib0034","article-title":"Bariatric surgery for non-alcoholic steatohepatitis in obese patients","volume":"2010","author":"Chavez-Tapia","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"10390","key":"10.1016\/j.ajpc.2024.100638_bib0035","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ajpc.2024.100638_bib0036","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s11695-014-1560-z","article-title":"Trends in weight regain following roux-en-Y gastric bypass (RYGB) bariatric surgery","volume":"25","author":"Cooper","year":"2015","journal-title":"Obes Surg"},{"issue":"15","key":"10.1016\/j.ajpc.2024.100638_bib0037","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/jama.2018.14433","article-title":"Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes","volume":"320","author":"King","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ajpc.2024.100638_bib0038","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11892-023-01498-z","article-title":"Weight regain after bariatric surgery: scope of the problem, causes, prevention, and treatment","volume":"23","author":"Noria","year":"2023","journal-title":"Curr Diab Rep"},{"issue":"3","key":"10.1016\/j.ajpc.2024.100638_bib0039","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ajpc.2024.100638_bib0040","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"B","year":"2013","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"5","key":"10.1016\/j.ajpc.2024.100638_bib0041","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator\u2212activated receptor\u2212\u03b1 and \u2212\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpc.2024.100638_bib0042","unstructured":"Genfit. A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of elafibranor in patients with nonalcoholic steatohepatitis (NASH) and Fibrosis. clinicaltrials.gov; 2022. [Accessed December 31, 2022]. https:\/\/clinicaltrials.gov\/study\/NCT02704403."},{"issue":"4","key":"10.1016\/j.ajpc.2024.100638_bib0043","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12072-015-9656-7","article-title":"Bile acids: emerging role in management of liver diseases","volume":"9","author":"Asgharpour","year":"2015","journal-title":"Hepatol Int"},{"issue":"11","key":"10.1016\/j.ajpc.2024.100638_bib0044","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.ajpc.2024.100638_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ajpc.2024.100638_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ajpc.2024.100638_bib0047","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ajpc.2024.100638_bib0048","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ajpc.2024.100638_bib0049","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/db09-1403","article-title":"C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis","volume":"59","author":"Obstfeld","year":"2010","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ajpc.2024.100638_bib0050","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3390\/medicina58060761","article-title":"An update on the chemokine system in the development of NAFLD","volume":"58","author":"Nagata","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"10.1016\/j.ajpc.2024.100638_bib0051","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2006.02.011","article-title":"Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2","volume":"44","author":"Haukeland","year":"2006","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.ajpc.2024.100638_bib0052","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1172\/JCI41732","article-title":"Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice","volume":"120","author":"Berres","year":"2010","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.ajpc.2024.100638_bib0053","first-page":"1858","article-title":"CCR1 and CCR5 promote hepatic fibrosis in mice","volume":"119","author":"Seki","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpc.2024.100638_bib0054","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","article-title":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design","volume":"47","author":"Friedman","year":"2016","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"10.1016\/j.ajpc.2024.100638_bib0055","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"issue":"0","key":"10.1016\/j.ajpc.2024.100638_bib0056","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"0","author":"Anstee","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.ajpc.2024.100638_bib0057","article-title":"New targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Rep"},{"issue":"17","key":"10.1016\/j.ajpc.2024.100638_bib0058","doi-asserted-by":"crossref","first-page":"11482","DOI":"10.1073\/pnas.132384699","article-title":"Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity","volume":"99","author":"Ntambi","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.ajpc.2024.100638_bib0059","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.gtc.2019.10.003","article-title":"Pharmacologic treatment strategies for nonalcoholic steatohepatitis","volume":"49","author":"Esteban","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"issue":"12","key":"10.1016\/j.ajpc.2024.100638_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"23","key":"10.1016\/j.ajpc.2024.100638_bib0061","doi-asserted-by":"crossref","first-page":"12797","DOI":"10.3390\/ijms222312797","article-title":"Hypothyroidism-associated dyslipidemia: potential molecular mechanisms leading to NAFLD","volume":"22","author":"Mavromati","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ajpc.2024.100638_bib0062","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1053\/j.gastro.2008.01.032","article-title":"Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone","volume":"134","author":"G\u00e4lman","year":"2008","journal-title":"Gastroenterology"},{"issue":"36","key":"10.1016\/j.ajpc.2024.100638_bib0063","doi-asserted-by":"crossref","first-page":"34114","DOI":"10.1074\/jbc.M305417200","article-title":"Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2)","volume":"278","author":"Shin","year":"2003","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.ajpc.2024.100638_bib0064","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.22572","article-title":"Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist","volume":"49","author":"Cable","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ajpc.2024.100638_bib0065","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchREV Endocrinol"},{"issue":"4","key":"10.1016\/j.ajpc.2024.100638_bib0066","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.ajpc.2024.100638_bib0067","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpc.2024.100638_bib0068","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2024.100638_bib0069","unstructured":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial | Nature Medicine. [Accessed October 9, 2023]. https:\/\/www.nature.com\/articles\/s41591-021-01425-3."},{"issue":"5","key":"10.1016\/j.ajpc.2024.100638_bib0070","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life's essential 8: updating and enhancing the American heart association's construct of cardiovascular health: a presidential advisory from the American heart association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667724000060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667724000060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:39:20Z","timestamp":1763005160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667724000060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":70,"alternative-id":["S2666667724000060"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2024.100638","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapies for MASLD and their impact on plasma lipids","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2024.100638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100638"}}